Synthesis and structural analysis of the N-terminal domain of the thyroid hormone-binding protein transthyretin

Clinical Chemistry and Laboratory Medicine

Volumn 40, Issue 12, 2002, Pages 1221-1228

  Wilce, Jackie A ^a   Daly, Norelle L ^b   Craik, David J ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Amyloid; Peptide synthesis; Protein fragments; Transthyretin

Indexed keywords

AMYLOID; LIGAND; MONOMER; PREALBUMIN; RETINOL; SULFIDE; TETRAMER; THYROXINE;

AMINO TERMINAL SEQUENCE; ANTIGEN RECOGNITION; BETA SHEET; CHEMICAL PROCEDURES; CONTROLLED STUDY; GEL ELECTROPHORESIS; GEL FILTRATION CHROMATOGRAPHY; HORMONE BINDING; HORMONE TRANSPORT; MEDICAL RESEARCH; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN STABILITY; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW; STRUCTURE ANALYSIS;

MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; PEPTIDE FRAGMENTS; PREALBUMIN; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; THYROID HORMONES;

EID: 0036910524     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2002.212     Document Type: Review

References (42)

1. Nilsson SF, Peterson PA. Studies on thyroid hormone-binding protein. I. The subunit structure of human thyroxine-binding globulin and its interaction with ligands. J Biol Chem 1975; 250:8543-53.
2. Monaco HL, Rizzi M, Coda A. Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein. Science 1995; 268:1039-41.
3. Blake CC, Geisow MJ, Oatley SJ, Rérat B, Rérat C. Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 Å. J Mol Biol 1978; 121:339-56.
4. Ciszak E, Cody V, Luft JR. Crystal structure determination at 2.3-A resolution of human transthyretin-3′,5′-dibromo-2′,4,4′,6-tetrahydroxyaurone complex. Proc Natl Acad Sci USA 1992; 89:6644-8.
5. Wojtczak A, Luft J, Cody V. Mechanism of molecular recognition. Structure aspects of 3,3′-diiodo-L-thyronine binding to human serum transthyretin. J Biol Chem 1992, 267: 353-7.
6. Hornberg A, Eneqvist T, Olofsson A, Lundgren E, Sauer-Eriksson AE. A comparative analysis of 23 structures of the amyloidogenic protein transthyretin. J Mol Biol 2000; 302:649-69.
7. Wojtczak A, Cody V, Luft J, Pangborn W. Structures of human transthyretin complexed with thyroxine at 2.0 Å resolution and 3′,5′-dinitro-N-acetyl-L-thyronine at 2.2 Å resolution. Acta Crystallogr D Biol Crystallogr 1996; 52:758-65.
8. Branch WT, Robbins J, Edelhoch H. Thyroxine-binding prealbumin. Conformation in urea and guanidine. Arch Biochem Biophys 1972; 152:144-51.
9. Saraiva MJ. Molecular genetics of familial amyloidotic polyneuropathy. J Peripher Nerv Syst 1996; 1:179-88.
10. Lai Z, Colon W, Kelly JW. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Biochemistry 1996; 35:6470-82.
11. Sunde M, Serpell LC, Bartlam M, Fraser PE, Pepys MB, Blake CC. Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J Mol Biol 1997; 273:729-39.
12. Jacobson DR, Buxbaum JN. Genetic aspects of amyloidosis. Adv Hum Genet 1991; 20:69-123.
13. McCutchen SL, Lai Z, Miroy GJ, Kelly JW, Colon W. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease. Biochemistry 1995; 34:13527-36.
14. Benson MD, Uemichi T. Transthyretin amyloidosis. Amyloid 1996; 3:44-56.
15. Kelly JW. The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr Opin Struct Biol 1998; 8:101-6.
16. Damas AM, Saraiva MJ. Review: TTR amyloidosis-structural features leading to protein aggregation and their implications on therapeutic strategies. J Struct Biol 2000; 130:290-9.
17. Hamilton JA, Benson MD. Transthyretin: a review from a structural perspective. Cell Mol Life Sci 2001; 58:1491-521.
18. Saraiva MJ. Transthyretin amyloidosis: a tale of weak interactions. FEBS Lett 2001; 498:201-3.
19. Miroy GJ, Lai Z, Lashuel HA, Peterson SA, Strang C, Kelly JW. Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc Natl Acad Sci USA 1996; 93: 15051-6.
20. Peterson SA, Klabunde T, Lashuel HA, Purkey H, Sacchettini JC, Kelly JW. Inhibiting transthyretin conformational changes that lead to amyloid fibril formation. Proc Natl Acad Sci USA 1998; 95:12956-60.
21. Klabunde T, Petrassi HM, Oza VB, Raman P, Kelly JW, Sacchettini JC. Rational design of potent human transthyretin amyloid disease inhibitors. Nat Struct Biol 2000; 7:312-21.
22. Wilce JA, Love SG, Richardson SJ, Alewood PF, Craik DJ. Synthesis of an analog of the thyroid hormone-binding protein transthyretin via regioselective chemical ligation. J Biol Chem 2001; 276:25997-6003.
23. Hammarstrom P, Schneider F, Kelly JW. Trans-suppression of misfolding in an amyloid disease. Science 2001; 293: 2459-62.
24. Englebretsen DR, Garnham BG, Bergman DA, Alewood PF. A novel thioether linker: chemical synthesis of a HIV-1 protease analogue by thioether ligation. Tetrahedron Lett 1995; 36:8871-4.
25. Schnolzer M, Alewood P, Jones A, Alewood D, Kent SB. In situ neutralization in Boc-chemistry solid phase peptide synthesis. Rapid, high yield assembly of difficult sequences. Int J Pept Protein Res 1992; 40:180-93.
26. Wishart DS, Sykes BD, Richards FM. Relationship between nuclear magnetic resonance chemical shift and protein secondary structure. J Mol Biol 1991; 222:311 -33.
27. Gustavsson A, Engstrom U, Westermark P. Normal transthyretin and synthetic transthyretin fragments form amyloid-like fibrils in vitro. Biochem Biophys Res Commun 1991; 175:1159-64.
28. Thylen C, Wahlqvist J, Haettner E, Sandgren O, Holmgren G, Lundgren E. Modifications of transthyretin in amyloid fibrils: analysis of amyloid from homozygous and heterozygous individuals with the Met30 mutation. EMBO J 1993; 12:743-8.
29. Jarvis JA, Kirkpatrick A, Craik DJ. 1H NMR analysis of fibril-forming peptide fragments of transthyretin. Int J Pept Protein Res 1994; 44:388-98.
30. Jarvis JA, Craik DJ, Wilce MC. X-ray diffraction studies of fibrils formed from peptide fragments of transthyretin. Biochem Biophys Res Commun 1993; 192:991-8.
31. MacPhee CE, Dobson CM. Chemical dissection and re-assembly of amyloid fibrils formed by a peptide fragment of transthyretin. J Mol Biol 2000; 297:1203-15.
32. Wilce JA, Salvatore D, Wade JD, Craik DJ. 1H-NMR structural studies of a cystine-linked peptide containing residues 71-93 of transthyretin and effects of a Ser84 substitution implicated in familial amyloidotic polyneuropathy. Eur J Biochem 1999; 262:586-94.
33. Jarvis JA, Munro SL, Craik DJ. Structural analysis of peptide fragment 71-93 of transthyretin by NMR spectroscopy and electron microscopy: insight into amyloid fibril formation. Biochemistry 1994; 33:33-41.
34. Najbar LV, Craik DJ, Wade JD, McLeish MJ. Identification of initiation sites for T4 lysozyme folding using CD and NMR spectroscopy of peptide fragments. Biochemistry 2000; 39:5911-20.
35. Najbar LV, Craik DJ, Wade JD, Salvatore D, McLeish MJ. Conformational analysis of LYS(11 -36), a peptide derived from the beta-sheet region of T4 lysozyme, in TFE and SDS. Biochemistry 1997; 36:11525-33.
36. Hamilton JA, Steinrauf LK, Liepnieks J, Benson MD, Holmgren G, Sandgren O, et al. Alteration in molecular structure which results in disease: the Met-30 variant of human plasma transthyretin. Biochim Biophys Acta 1992; 1139: 9-16.
37. Terry CJ, Damas AM, Oliveira P, Saraiva MJ, Alves IL, Costa PP, et al. Structure of Met30 variant of transthyretin and its amyloidogenic implications. EMBO J 1993; 12:735-41.
38. Hamilton JA, Steinrauf LK, Braden BC, Liepnieks J, Benson MD, Holmgren G, et al. The X-ray crystal structure refinements of normal human transthyretin and the amyloidogenic Val-30→Met variant to 1.7-Å resolution. J Biol Chem 1993; 268:2416-24.
39. Purkey HE, Dorrell MI, Kelly JW. Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma. Proc Natl Acad Sci USA 2001; 98:5566-71.
40. Munro SL, Lim CF, Hall JG, Barlow JW, Craik DJ, Topliss DJ, et al. Drug competition for thyroxine binding to transthyretin (prealbumin): comparison with effects on thyroxine-binding globulin. J Clin Endocrinol Metab 1989; 68:1141-7.
41. Oza VB, Smith C, Raman P, Koepf EK, Lashuel HA, Petrassi HM, et al. Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors. J Med Chem 2002; 45:321-32.
42. Petrassi HM, Klabunde T, Sacchettini JW, Kelly JW. Structure-based design of N-phenyl phenoxazine transthyretin amyloid fibril inhibitors. J Am Chem Soc 2000; 122: 2178-92.